Taxane-induced peripheral neuropathy more common in patients with diabetes longer than 5 years
the ONA take:
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for developing severe peripheral sensory neuropathy, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers in Turkey sought to determine whether the presence of diabetes mellitus impacts the incidence and severity of peripheral sensory neuropathy in patients undergoing taxane therapy for cancer. Researchers retrospectively analyzed data from 374 patients receiving taxane therapy at a single institution. Of those, 21.6% had diabetes.
Results showed that the incidence of grade 1 peripheral neuropathy in patients receiving taxane-based therapy was 33.4% in non-diabetics and 25.9% in those with diabetes; however, the incidence of grade 2 or higher peripheral neuropathy was 15% and 34.6%, respectively.
Researchers found that the overall incidence of peripheral neuropathy was 48.8% in non-diabetic patients, 52.8% in patients with diabetes less than 5 years, and 75% in patients with diabetes for longer than 5 years.
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for neuropathy.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|